US Edition
Paradigm Capital doubles its price target on NervGen Pharma
Summary by Cantech Letter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Paradigm Capital doubles its price target on NervGen Pharma
Paradigm Capital has doubled its price target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN) to $9.70, with analyst Scott McAuley maintaining a “Speculative Buy” rating on June 16 after early trial data showed signs the company’s treatment could help the central nervous system repair itself following spinal cord injury. “The […] Source
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
